Why Your BMI Means Different Things in Asia

If you've ever calculated your BMI and concluded "I'm fine — I'm only 26," you may be working from the wrong reference range.

The standard BMI categories most people know — overweight at 25, obese at 30 — were developed primarily from data on European and North American populations. Applied to Asian populations, those thresholds systematically miss the patients most at risk for metabolic disease.

What the evidence shows

In 2004, a WHO Expert Consultation reviewed extensive epidemiological data from Asian populations and concluded that the relationship between BMI and metabolic risk differs meaningfully between Asian and European populations. At any given BMI, Asian populations have higher percentage body fat, more visceral adiposity, and higher rates of type 2 diabetes, hypertension, and dyslipidemia than European populations. ¹

The practical implication: an Asian patient with BMI 25 carries metabolic risk equivalent to a European patient with BMI 30. Using the same threshold for both groups means the Asian patient — already at clinically significant risk — does not meet treatment criteria, while the European patient does.

The WHO consultation recommended an Asia-Pacific–specific classification:

• BMI ≥ 23 — overweight (vs. ≥ 25 for general WHO classification)

• BMI ≥ 27.5 — obese (vs. ≥ 30 for general WHO classification)

This is not a relabeling exercise. It reflects different biology.

Why the difference exists

Several factors contribute to the divergence between Asian and European BMI-risk relationships:

• Body composition. At any given BMI, Asian populations carry more body fat and less skeletal muscle mass than European populations. BMI doesn't distinguish fat from muscle, so the same BMI represents different metabolic situations.

• Fat distribution. Asian populations tend toward central (abdominal/visceral) fat deposition rather than peripheral (subcutaneous) deposition. Visceral fat is metabolically more dangerous — it correlates more strongly with insulin resistance, fatty liver, and cardiovascular events.

• Insulin sensitivity. Even at lower BMI, Asian populations show earlier-onset insulin resistance and earlier loss of beta cell function in the pancreas. Type 2 diabetes appears at BMI levels where European populations would still be considered metabolically healthy. ²

• Genetic and epigenetic factors. The "thrifty phenotype" hypothesis suggests that populations evolved in environments of intermittent food scarcity may carry genetic adaptations that promote efficient fat storage — which becomes maladaptive in modern food environments.

What this means for treatment thresholds

For pharmacological weight management — including GLP-1 medications like Semaglutide and Tirzepatide — the FDA and EMA labeling thresholds are based on Western data:

• BMI ≥ 30 (obesity), or

• BMI ≥ 27 with at least one weight-related comorbidity

Applied to Asian patients, these thresholds are clinically too high. An Asian patient with BMI 27 and no diagnosed comorbidity may already have early insulin resistance, elevated liver enzymes, or pre-diabetes — but appears outside the labeled population for GLP-1 therapy.

At Siam Clinic, we use ethnicity-adjusted thresholds for treatment evaluation:

• BMI ≥ 27.5 (Asian) or ≥ 30 (Western) — primary obesity threshold

• BMI ≥ 23 (Asian) or ≥ 27 (Western) with weight-related comorbidity

This is consistent with how diabetes screening is now performed in Asia: the American Diabetes Association recommends screening for type 2 diabetes at BMI ≥ 23 in patients of Asian ancestry — not the standard ≥ 25 used for other populations. ³

Using Western BMI thresholds for Asian patients is not a clinical conservatism. It's a systematic under-treatment of the population most at risk.

What patients can do

If you are of Asian ancestry and your BMI falls between 23 and 27.5, the standard "you're fine, you're only overweight" conclusion may be incomplete. The relevant questions are:

• What is my fasting glucose and HbA1c?

• What is my liver enzyme panel (ALT, AST, GGT)?

• What is my fasting insulin — or HOMA-IR if calculated?

• What does my lipid profile look like, particularly triglycerides and HDL?

• What is my body composition — specifically visceral adiposity, not just BMI?

If any of these markers show early disease, the case for active intervention strengthens — even at "normal-by-Western-standards" BMI.

If you'd like to assess your own risk profile against ethnicity-specific criteria, our Candidates page walks through the framework. For a personalized assessment, book a 45-minute consultation — we'll review labs, body composition, and family history alongside BMI.

Tagged
bmi asian-population evidence-based

Medically reviewed
Siam Clinic Medical Team
All clinical claims verified against peer-reviewed sources. How we write & cite →

References

• WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163. doi:10.1016/S0140-6736(03)15268-3

• Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681-1688. doi:10.1016/S0140-6736(06)69703-1

• American Diabetes Association Professional Practice Committee. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. doi:10.2337/dc24-S002